Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 in HER2-negative hormone receptor-positive breast cancer with bone metastases
CTR20150754Phase 2Active
- Sponsor
- Bayer
- Start
- Aug 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in breast cancer, sponsored by Bayer. Started Aug 2016; status: active.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20150754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150754.